Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence
-
Douglas Guedes de Castro [1] ; Carlos Henrique Andrade Teixeira [1] ; Guilherme Rocha Melo Gondim [1] ; Patrícia Bailão Aguilar [1] ; Marcos André de Sá Barreto Costa [1] ; Thiago William Carnier Jorge [1] ; Rodrigo de Morais Hanriot [1]
-
[1] Hospital Alemão Oswaldo Cruz
Hospital Alemão Oswaldo Cruz
Brasil
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 9, 2022, págs. 1828-1830
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting.
Methods/patients The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan–Meier and log-rank test was applied.
Results After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P = .0034).
Conclusions This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.
